HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Boscher C, Dubot-Poitelon C, Rottier P, Lequesne J, Emile G.
Cherifi F, et al. Among authors: villemin m.
BMC Cancer. 2022 Oct 20;22(1):1081. doi: 10.1186/s12885-022-10163-9.
BMC Cancer. 2022.
PMID: 36266623
Free PMC article.